Related Experiment Video
Updated: Jun 5, 2026
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
Advances in EGFR-directed therapy in head and neck cancer
Gianmauro Numico1, Nicola Silvestris, Elvio Grazioso Russi
1SC Oncologia; Azienda USL della Valle d'Aosta, Aosta, Italy. gnumico@ausl.vda.it
Abstract:
Initial research showed that EGFR targeting through known single agents, both monoclonal antibodies and small-molecule tyrosine-kinase inhibitors, applied to patients with refractory head and neck cancer, resulted in low response rates and short median survival times. However, the combination of Cetuximab with radiotherapy in patients with locally advanced disease and with a combination of platinum and fluorouracil in the setting of relapsed and/or metastatic disease resulted in a sharp improvement compared to standard therapy. Cetuximab entered clinical practice in both indications. Other anti-EGFR drugs, although showing activity, have not demonstrated an improvement of the results of standard therapy. Unfortunately, no molecular parameter emerged as a useful tool in predicting activity, thus impairing clinical applications. Only skin rash was repeatedly shown to be related with drug activity. Although generally well tolerated, class and drug specific toxicities can be troublesome and require knowledge and expertise for an optimal management. Further research is needed in order to find the best ways of integrating the anti-EGFR strategy with current standards of care.
Insights
Cetuximab shows improved outcomes for head and neck cancer when combined with standard therapies, though predicting patient response remains a challenge. Further research is needed to optimize epidermal growth factor receptor (EGFR) targeted strategies.
Area of Science:
- Oncology
- Pharmacology
Background:
- Epidermal growth factor receptor (EGFR) targeting in head and neck cancer with single agents yielded limited success.
- Previous treatments for refractory head and neck cancer showed low response rates and survival times.
Purpose of the Study:
- To evaluate the efficacy of Cetuximab, an anti-EGFR drug, in combination with standard therapies for head and neck cancer.
- To assess the predictive value of molecular parameters and clinical factors for anti-EGFR drug activity.
Main Methods:
- Review of clinical data on anti-EGFR agents, including Cetuximab, in head and neck cancer patients.
- Analysis of combination therapies involving Cetuximab with radiotherapy or chemotherapy.
- Correlation of clinical outcomes with molecular markers and adverse events like skin rash.
Main Results:
- Combination of Cetuximab with radiotherapy (locally advanced disease) or chemotherapy (relapsed/metastatic disease) significantly improved outcomes compared to standard care.
- Cetuximab is now in clinical practice for these indications.
- No reliable molecular predictor of efficacy was identified; skin rash was associated with activity.
Conclusions:
- Cetuximab-based combination therapies represent a significant advancement in head and neck cancer treatment.
- Optimal management of toxicities associated with anti-EGFR drugs is crucial.
- Further investigation is required to refine the integration of anti-EGFR strategies into standard care.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:38Mitogens and the Cell Cycle
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:27Tumor Immunotherapy
02:56Treatment Resistent Cancers